Randomised phase II trial of carboplatin and iproplatin in advanced urothelial cancer (Q33325046)

25 July 2017

title

Randomised phase II trial of carboplatin and iproplatin in advanced urothelial cancer (English)

1 reference

25 July 2017

main subject

phase II clinical trial

0 references

1 reference

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90015-6

6 December 2022

4

Seynaeve C

1 reference

25 July 2017

R. de Wit

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1835851

6 December 2022

M. Tesselaar

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1835851

6 December 2022

T. C. Kok

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1835851

6 December 2022

C. J. Rodenburg

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1835851

6 December 2022

J. Verweij

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1835851

6 December 2022

P. A. Helle

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1835851

6 December 2022

G. Stoter

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1835851

6 December 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1835851

6 December 2022

publication date

1 January 1991

1 reference

full work available at URL

25 July 2017

https://api.elsevier.com/content/article/PII:0277537991900156?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90015-6

https://api.elsevier.com/content/article/PII:0277537991900156?httpAccept=text/plain

6 December 2022

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90015-6

European Journal of Cancer

6 December 2022

published in

1 reference

25 July 2017

volume

27

1 reference

25 July 2017

issue

11

1 reference

25 July 2017

page(s)

1383-1385

1 reference

A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract

25 July 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90015-6

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors

6 December 2022

4

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90015-6

Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder

6 December 2022

7

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90015-6

Nephrotoxicity of cis-platinum (II) dichlorodiammine

6 December 2022

8

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90015-6

A strategy for the development of two clinically active cisplatin analogs: CBDCA and CHIP.

6 December 2022

9

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90015-6

Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.

6 December 2022

10

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90015-6

Iproplatin and carboplatin induced toxicities: overview of phase II clinical trial conducted by the EORTC Early Clinical Trials Cooperative Group (ECTG).

6 December 2022

12

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90015-6

The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent

6 December 2022

14

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90015-6

Hypersensitivity reactions to CHIP.

6 December 2022

15

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90015-6

Phase II study of carboplatin in locally advanced and metastatic transitional cell carcinoma of the urinary bladder

6 December 2022

16

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90015-6

Methotrexate, cisplatin and carboplatin as single agents and in combination for metastatic bladder cancer

6 December 2022

18

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90015-6

Carboplatin for advanced bladder cancer

6 December 2022

20

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90015-6

Phase III comparison of cisplatin alone versus cisplatin, doxorubicin and cyclophosphamide in the treatment of bladder (urothelial) cancer: a Southeastern Cancer Study Group trial

6 December 2022

22

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90015-6

Comparative activity and toxicity of cis-diamminedichloroplatinum (DDP) and a combination of doxorubicin, cyclophosphamide, and DDP in disseminated transitional cell carcinomas of the urinary tract

6 December 2022

23

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90015-6

6 December 2022

Identifiers

1 reference

25 July 2017

1 reference